Rather than being reserved only for a specific clinical context, the combined biopsy approach appears to have a broad role in the advanced tumor treatment landscape, with particular value in cases with multiple metastases or high tumor fraction or when targeting specific molecular pathways. The ROM trial provides strong evidence that integrating tissue and liquid biopsies enhances the precision of cancer diagnostics and treatment outcomes in advanced solid tumors...
Rather than being reserved only for a specific clinical context, the combined biopsy approach appears to have a broad role in the advanced tumor treatment landscape, with particular value in cases with multiple metastases or high tumor fraction or when targeting specific molecular pathways. The ROM trial provides strong evidence that integrating tissue and liquid biopsies enhances the precision of cancer diagnostics and treatment outcomes in advanced solid tumors. As technology advances and costs potentially decrease, combined biopsies are likely to become increasingly integrated into standard oncology practice. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
